Latest Market Entry News

Almonty Industries has filed for a Nasdaq listing and launched a U.S. public offering to fund its tungsten oxide facility and strengthen its global supply position amid rising geopolitical tensions.

EVE Health Group has placed its first commercial purchase order for Dyspro™, a cannabinoid-based pharmaceutical targeting painful menstruation, signaling a key step toward market entry. The product is set for manufacturing and distribution within weeks, tapping into a rapidly growing global women’s health market.

Terragen Holdings has been granted a US patent for its microbial feed supplements, reinforcing its position in the animal probiotics market and supporting plans for US market entry.

Neurizon Therapeutics has inked a pivotal global licensing deal with Elanco Animal Health, unlocking critical intellectual property and data to accelerate the development and commercialisation of its lead drug candidate NUZ-001 for neurodegenerative diseases including ALS.

Echo IQ has initiated a pivotal clinical validation study with the Mayo Clinic Platform to test its EchoSolv HF software, marking the final step before its planned FDA submission in late 2025.

Green Critical Minerals’ McIntosh Graphite Project Pre-Feasibility Study confirms robust economics with a post-tax NPV of A$235 million and a 32.5-year mine life, underpinning plans for staged development and market entry.

LTR Pharma has successfully completed the extractables study for its intranasal erectile dysfunction spray SPONTAN, confirming safety compliance and initiating the next phase of leachables testing to support FDA approval.

Memphasys Limited has submitted its CE Mark application for the Felix™ sperm separation device, targeting regulatory clearance within 6-12 months to unlock the lucrative European IVF market and accelerate approvals in other key regions.

Canyon Resources has secured a significant credit facility and advanced key contracts, setting the stage for production and first bauxite shipments from its Minim Martap project in early 2026.

Firebird Metals has reported promising lab-scale results for its lithium manganese iron phosphate cathode material, showing a significant energy density improvement over standard LFP. The company is moving towards pilot-scale production and global commercialisation.

Rhythm Biosciences has regained NATA accreditation for its geneType laboratory, a key step toward commercialising its ColoSTAT® cancer risk test as an in-house diagnostic.

Microba Life Sciences has raised $14.5 million to accelerate clinical adoption of its microbiome testing products, while narrowing its FY25 revenue guidance and signing a strategic UK laboratory agreement.